Biotech · Private company
MeiraGTx UK II Ltd
Track this companyFree. Adds MeiraGTx UK II Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- AAV - CNGB3Phase 2 · AchromatopsiaClinicalTrials.gov · fetched Nov 12, 2026
- AAV RPE65Phase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
- AAV5-RPGRPhase 2 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- adeno-associated virus vector AAV- CNGA3Phase 2 · AchromatopsiaClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 1 x 10^11 vg/gland (both glands)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 1 x 10^11 vg/gland (single gland)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 1 x 10^12 vg/gland (single gland)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 3 x 10^10 vg/gland (both glands)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 3 x 10^11 vg/gland (both glands)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV2hAQP1: 3 x 10^11 vg/gland (single gland)Phase 1 · Radiation-Induced Parotid Gland HypofunctionClinicalTrials.gov · fetched Nov 12, 2026
- AAV OPTIRPE65Leber Congenital Amaurosis (LCA)ClinicalTrials.gov · fetched Nov 12, 2026
- Prior exposure to AAV-CNGA3 or AAV-CNGB3AchromatopsiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Gene Therapy for Achromatopsia (CNGA3)PHASE1_PHASE2 · COMPLETED · started Aug 12, 2019ClinicalTrials.gov NCT03758404 · fetched Nov 12, 2026
- A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and XerostomiaPHASE1 · COMPLETED · started Jun 30, 2019ClinicalTrials.gov NCT04043104 · fetched Nov 12, 2026
- Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)COMPLETED · started Dec 19, 2017ClinicalTrials.gov NCT03349242 · fetched Nov 12, 2026
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)PHASE1_PHASE2 · COMPLETED · started Jul 31, 2017ClinicalTrials.gov NCT03252847 · fetched Nov 12, 2026
- Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3TERMINATED · started Jun 29, 2017ClinicalTrials.gov NCT03278873 · fetched Nov 12, 2026
- Gene Therapy for Achromatopsia (CNGB3)PHASE1_PHASE2 · COMPLETED · started Jan 16, 2017ClinicalTrials.gov NCT03001310 · fetched Nov 12, 2026
- Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)COMPLETED · started Nov 1, 2016ClinicalTrials.gov NCT02946879 · fetched Nov 12, 2026
- Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)PHASE1_PHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02781480 · fetched Nov 12, 2026
- Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02714816 · fetched Nov 12, 2026